Alan R. Hay

2.9k total citations · 1 hit paper
8 papers, 2.2k citations indexed

About

Alan R. Hay is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Urology. According to data from OpenAlex, Alan R. Hay has authored 8 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 2 papers in Surgery and 2 papers in Urology. Recurrent topics in Alan R. Hay's work include Prostate Cancer Treatment and Research (4 papers), Prostate Cancer Diagnosis and Treatment (3 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). Alan R. Hay is often cited by papers focused on Prostate Cancer Treatment and Research (4 papers), Prostate Cancer Diagnosis and Treatment (3 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). Alan R. Hay collaborates with scholars based in United States. Alan R. Hay's co-authors include John E. McNeal, Fuad S. Freiha, Thomas A. Stamey, Elise A. Redwine, Norman Yang, Joel W. Hay, Yang Na, Richard Levin, Ivan Grunberger and Mohamed Bidair and has published in prestigious journals such as New England Journal of Medicine, The Journal of Urology and Journal of Clinical Gastroenterology.

In The Last Decade

Alan R. Hay

7 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate

1987 1.9k citations Thomas A. Stamey, Norman Yang et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Alan R. Hay

Since Specialization

Citations

This map shows the geographic impact of Alan R. Hay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan R. Hay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan R. Hay more than expected).

Fields of papers citing papers by Alan R. Hay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan R. Hay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan R. Hay. The network helps show where Alan R. Hay may publish in the future.

Co-authorship network of co-authors of Alan R. Hay

This figure shows the co-authorship network connecting the top 25 collaborators of Alan R. Hay. A scholar is included among the top collaborators of Alan R. Hay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan R. Hay. Alan R. Hay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis 2022 ·BMC Urology ·(unknown), Joel W. Hay, Alan R. Hay, Sze‐chuan Suen	0
2	Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results 2020 ·World Journal of Urology ·Neal D. Shore, Steven A. Kaplan, Ronald Tutrone, Richard Levin, James L. Bailen, Alan R. Hay, (unknown), Mohamed Bidair, Sheldon Freedman, Kenneth Goldberg, (unknown), Jonathan I. Epstein	2
3	Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement 2018 ·World Journal of Urology ·Neal D. Shore, Ronald Tutrone, Mitchell Efros, Mohamed Bidair, Barton Wachs, (unknown), Sheldon Freedman, James L. Bailen, Richard Levin, Stephen K. Richardson, Jed Kaminetsky, Jeffrey A. Snyder, (unknown), Kenneth Goldberg, Alan R. Hay, Steven Gange, Ivan Grunberger	13
4	Inflammatory Bowel Disease 1992 ·Journal of Clinical Gastroenterology ·Joel W. Hay, Alan R. Hay	201
5	Inflammatory Bowel Disease 1992 ·Journal of Clinical Gastroenterology ·Alan R. Hay, Joel W. Hay	95
6	Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate 1988 ·The Journal of Urology ·Thomas A. Stamey, Yang Na, Alan R. Hay, John E. McNeal, Fuad S. Freiha, Elise A. Redwine	27
7	Am Evaluation of Prostate-Specific Antigen in the Diagnosis and Treatment of Prostate Cancer 1987 ·The Journal of Urology ·Thomas A. Stamey, Alan R. Hay, John E. McNeal, Fuad S. Freiha	3
8	Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate breakdown → 1987 ·New England Journal of Medicine ·Thomas A. Stamey, Norman Yang, Alan R. Hay, John E. McNeal, Fuad S. Freiha, Elise A. Redwine	1905

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact